Could Pfizer Be a No-Brainer Stock to Buy Right Now, Even If Its COVID Sales Continue to Plunge?
You might call it a "Pfizzle."
In late 2021, (NYSE: PFE) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine.
It followed that success with the launch of an effective oral COVID pill. Both became megablockbusters, with the vaccine (Comirnaty) generating global sales of $37.8 billion and the antiviral therapy (Paxlovid) raking in an additional $18.9 billion in 2022.
Source Fool.com